Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × lanreotide × Endocrine × Clear all

Phase

Status

Completed 7 Unknown 5 Recruiting 4 Terminated 3 Withdrawn 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

Pheochromocytoma 1 Paraganglioma 1

Interventions

lutetium Lu 177 dotatate 14 Nivolumab 10 Specimen Handling 9 Magnetic Resonance Spectroscopy 9 Ipilimumab 8 pembrolizumab 6 cabozantinib 6 Temozolomide 6 trametinib 5 dabrafenib 4 Immunoglobulin G 4 Everolimus 4 Disulfides 4 selpercatinib 3 lenvatinib 3 atezolizumab 3 Octreotide 3 Lutetium-177 3 Carboplatin 3 Capecitabine 3 CTLA-4 Antigen 3 Bevacizumab 3 gallium Ga 68 dotatate 2 entrectinib 2 copper dotatate CU-64 2 amino-acid, glucose, and electrolyte solution 2 X-Rays 2 Vemurafenib 2 Radionuclide Imaging 2 Positron-Emission Tomography 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03946527 2026-03-02

LAMPARA

Columbia University

Phase 2 Active not recruiting

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡